Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study.
Hilde Marie Torgauten, Kjell-Morten Myhr, Stig Wergeland...
https://pubmed.ncbi.nlm.nih.gov/33796328/Actively Recruiting
Led by Cairo University · Updated on 2026-03-18
46
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether rituximab can improve thinking skills and hand functions in people with secondary progressive multiple sclerosis SPMS who have significant disability EDSS score of 6.5 or higher. This phase 2 randomized controlled trial compares rituximab to a placebo to understand its effects on cognition, hand function, quality of life, and disability level as measured by the Expanded Disability Status Scale EDSS. Participants demographic and clinical information such as age, gender, disease duration, and EDSS scores will be collected. Participants will be randomly assigned to receive either rituximab or placebo infusions. The rituximab group will get an initial total dose of 1 gram divided into two 500 mg infusions two weeks apart, followed by another 1 gram infusion after six months, all given intravenously diluted in 500 ml of normal saline. The placebo group will receive 500 ml of normal saline infusions on the same schedule. The study lasts for one year with treatments and assessments throughout this period. During the study, participants will undergo tests including the Symbol Digit Modalities Test, Brief Visuospatial Memory Test-Revised, California Verbal Learning Test-II, and the Nine-Hole Peg Test to assess cognition and hand function. Quality of life and disability status using the EDSS will also be measured. These assessments will be done at baseline and after one year of treatment. The trial includes regular monitoring to evaluate the effects of rituximab and to ensure participant safety.
CONDITIONS
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
A
Amgad Mahmoud Elmeligy, MSc Neurology
A
Amr Mohamed Fouad, MD Neurology
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cairo University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive intravenous infusions of Rituximab or placebo according to their assigned group.
2 infusion visits in the first 2 weeks and 1 infusion visit at 6 months
Duration - Up to 6 months after last infusion, totaling 1 year from treatment start
Participants are monitored to assess the effects of treatment on cognitive and hand functions over one year.
Regular assessments during the year
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hilde Marie Torgauten, Kjell-Morten Myhr, Stig Wergeland...
https://pubmed.ncbi.nlm.nih.gov/33796328/Ilaria Carpinella, Davide Cattaneo, Maurizio Ferrarin
https://pubmed.ncbi.nlm.nih.gov/24745972/Yvonne Naegelin, Peter Naegelin, Stefanie von Felten...
https://pubmed.ncbi.nlm.nih.gov/30615019/Saeideh Salehizadeh, Roghayyeh Saeedi, Mohammad Ali Sahraian...
https://pubmed.ncbi.nlm.nih.gov/35974939/Bruno Brochet, Pierre Clavelou, Gilles Defer...
https://pubmed.ncbi.nlm.nih.gov/35203948/Cairo University
Lead Sponsor